Identification
Name3-Deoxyguanosine
Accession NumberDB03609  (EXPT00167)
TypeSmall Molecule
GroupsExperimental
Description

3-deoxyguanosine is a solid. This compound belongs to the purine nucleosides and analogues. These are compounds comprising a purine base attached to a sugar. This medication targets the protein purine nucleoside phosphorylase.

Structure
Thumb
SynonymsNot Available
External IDs Not Available
Product Ingredients Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNIINot Available
CAS numberNot Available
WeightAverage: 267.2413
Monoisotopic: 267.096753929
Chemical FormulaC10H13N5O4
InChI KeyOROIAVZITJBGSM-OBXARNEKSA-N
InChI
InChI=1S/C10H13N5O4/c11-10-13-7-6(8(18)14-10)12-3-15(7)9-5(17)1-4(2-16)19-9/h3-5,9,16-17H,1-2H2,(H3,11,13,14,18)/t4-,5+,9+/m0/s1
IUPAC Name
9-[(2R,3R,5S)-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-imino-3,9-dihydro-2H-purin-6-ol
SMILES
[H][C@@]1(CO)C[C@@]([H])(O)[C@@]([H])(O1)N1C=NC2=C1NC(=N)N=C2O
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of action
TargetKindPharmacological actionActionsOrganismUniProt ID
Purine nucleoside phosphorylaseProteinunknownNot AvailableHumanP00491 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions Not Available
Food InteractionsNot Available
References
Synthesis Reference

Tetsuro Fujishima, "Process for producing 3-deoxyguanosine." U.S. Patent US4594320, issued April, 1983.

US4594320
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials Not Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility9.05 mg/mLALOGPS
logP-1.5ALOGPS
logP-1.7ChemAxon
logS-1.5ALOGPS
pKa (Strongest Acidic)6.09ChemAxon
pKa (Strongest Basic)4.93ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area135.98 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity74.11 m3·mol-1ChemAxon
Polarizability25.13 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9974
Blood Brain Barrier+0.9621
Caco-2 permeable-0.8757
P-glycoprotein substrateNon-substrate0.6331
P-glycoprotein inhibitor INon-inhibitor0.9637
P-glycoprotein inhibitor IINon-inhibitor0.9353
Renal organic cation transporterNon-inhibitor0.9336
CYP450 2C9 substrateNon-substrate0.8606
CYP450 2D6 substrateNon-substrate0.8345
CYP450 3A4 substrateNon-substrate0.5919
CYP450 1A2 substrateNon-inhibitor0.8165
CYP450 2C9 inhibitorNon-inhibitor0.9408
CYP450 2D6 inhibitorNon-inhibitor0.9559
CYP450 2C19 inhibitorNon-inhibitor0.9594
CYP450 3A4 inhibitorNon-inhibitor0.9725
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9879
Ames testNon AMES toxic0.6292
CarcinogenicityNon-carcinogens0.8629
BiodegradationNot ready biodegradable0.9496
Rat acute toxicity1.9353 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9852
hERG inhibition (predictor II)Non-inhibitor0.9622
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as purine 3'-deoxyribonucleosides. These are compounds consisting of a purine linked to a ribose which lacks a hydroxyl group at position 3.
KingdomChemical entities
Super ClassOrganic compounds
ClassNucleosides, nucleotides, and analogues
Sub ClassPurine nucleosides
Direct ParentPurine 3'-deoxyribonucleosides
Alternative Parents6-oxopurines / Hypoxanthines / Pyrimidones / Aminopyrimidines and derivatives / Primary aromatic amines / N-substituted imidazoles / Vinylogous amides / Oxolanes / Heteroaromatic compounds / Secondary alcohols
SubstituentsPurine 3'-deoxyribonucleoside / 6-oxopurine / Hypoxanthine / Purinone / Imidazopyrimidine / Purine / Pyrimidone / Aminopyrimidine / Pyrimidine / Primary aromatic amine
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptorsguanosines, 3'-deoxyribonucleoside (CHEBI:39874 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Purine-nucleoside phosphorylase activity
Specific Function:
The purine nucleoside phosphorylases catalyze the phosphorolytic breakdown of the N-glycosidic bond in the beta-(deoxy)ribonucleoside molecules, with the formation of the corresponding free purine bases and pentose-1-phosphate.
Gene Name:
PNP
Uniprot ID:
P00491
Molecular Weight:
32117.69 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Drug created on June 13, 2005 07:24 / Updated on June 11, 2017 20:48